Ogier recently acted as Cayman and BVI counsel to Biostime, a leading Chinese producer of infant nutritional products, enabling it to raise a $850m of new financing as part of a combined capital markets and bank fundraising exercise.
The transaction involved the combination of new $400m 7.25% high-yield notes, due 2021, as well as a $450m term loan facility and a tender offer for Biostime’s existing HK$3.1bn Convertible Bonds, due 2019.